The first part of cold laser technology firm Theralase Technologies Inc’s (CVE:TLT) phase Ib bladder cancer trial has gone well.
The primary and secondary objectives for the first part of the non-muscle invasive bladder cancer (NMIBC) clinical study were successfully met, the independent data and safety monitoring board unanimously determined.
The plan now is to sign-up another six patients for the second part of the study, in which they will be treated with a therapeutic dose of the photo dynamic compound (PDC) for NMIBC using Theralase’s photo dynamic therapy (PDT) technology.
"I am delighted that a small Canadian company, such as Theralase, has been able to achieve such significant clinical results and in such a short time span. I look forward to Theralase reporting out on the next six patients using the therapeutic dose," said Dr Michael Jewett, uro-oncologist at the University Health Network.
Theralase’s boss and founder, Roger Dumoulin-White, thanked the data and safety monitoring board for performing the review.
“Theralase looks forward to successfully reporting out on the performance to the primary and secondary endpoints for the next six patients and also the exploratory objective of efficacy of all nine patients, as more clinical data is collected,” Dumoulin-White said.
“Theralase has now successfully transformed from a pre-clinical to a clinical oncology organization,” he added.